SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME
Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.
Video navigation menu
- EMPA-REG OUTCOME: eGFR over 3 years 02:32
- New onset or worsening of nephropathy 04:20
- Outcome in patients with pre-existing CKD (renal population) 08:28
- New onset or worsening of nephropathy: subgroup analysis 10:06
- Safety 12:30
This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.
Professor Christoph Wanner, MD - University of Würzburg, Germany
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.